α-Fetoprotein (AFP), Tumor Marker (Serial Monitor)
Also known as: Alpha-Fetoprotein (AFP), Serum, Tumor Marker (Serial Monitor)
Use
The α-Fetoprotein (AFP), Tumor Marker (Serial Monitor) test is primarily used in the long-term serial monitoring of Alfa-Fetoprotein levels in patients who may be undergoing treatment or monitoring for certain types of cancers, particularly liver cancer and some germ cell tumors. Serial monitoring allows for the tracking of AFP levels over time to observe changes and assess the effectiveness of treatment or check for recurrence.
Special Instructions
The account must submit the patient's Social Security number to monitor. Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. To order this test without the serial monitor service, see α-Fetoprotein (AFP), Tumor Marker [002253]. This test may show interference when collected from a person consuming a high dose of biotin. Patients should stop biotin consumption at least 72 hours before sample collection.
Limitations
Results obtained with different assay methods or kits cannot be used interchangeably. This test should not be interpreted as absolute evidence of the presence or absence of malignant disease. It is not interpretable in pregnant females due to naturally occurring high levels of AFP. Interference may occur with biotin-rich supplements.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 53962-7
- 53962-7
- 80563-0
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
Patients should stop biotin consumption at least 72 hours before sample collection.
Storage Instructions
Room temperature